Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
364 studies found for:    Open Studies | "Myelodysplastic Syndromes"
Show Display Options
Rank Status Study
1 Not yet recruiting A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Omacetaxine;   Drug: Azacitidine;   Drug: G-CSF
2 Recruiting Study of DSP-7888 in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: DSP-7888
3 Recruiting Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Biological: MEDI4736 Evaluate MEDI4736 in MDS;   Drug: VIDAZA;   Biological: tremelimumab
4 Recruiting Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Imetelstat;   Drug: Placebo
5 Recruiting 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Azacitidine
6 Recruiting PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.
Condition: Myelodysplastic Syndromes
Interventions: Other: research of disease-related factors;   Other: research of comorbidities;   Other: physical performance
7 Recruiting Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: Antibiotic and antifungal drugs
8 Recruiting Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Lenalidomide;   Other: Placebo
9 Recruiting Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: CC-486 (ORAL AZACITIDINE);   Drug: Durvalumab
10 Not yet recruiting Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndrome
Interventions: Drug: GSK2879552;   Drug: Azacitidine
11 Recruiting The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
Condition: Myelodysplastic Syndromes (MDS)
Intervention:
12 Recruiting Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Interventions: Drug: Sertraline;   Procedure: Bone Marrow Aspirate/Biopsy
13 Recruiting Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: vosaroxin;   Drug: Azacitidine
14 Recruiting Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)
Condition: Myelodysplastic Syndromes
Interventions: Behavioral: Question prompt list (QPL);   Behavioral: Education brochure of Groupe Français des Myélodysplasies
15 Recruiting ACE-536 Extension Study - Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: ACE-536
16 Recruiting Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Procedure: Best Supportive Care;   Drug: BI 836858
17 Recruiting Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: CG200745 PPA
18 Recruiting Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: selinexor (KPT-330)
19 Recruiting A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: OPN-305
20 Recruiting Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: Tipifarnib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.